X-linked Charcot-Marie-Tooth disease, Arts syndrome, and prelingual non-syndromic deafness form a disease continuum: evidence from a family with a novel PRPS1 mutation

Matthis Synofzik1,2*, Jennifer Müller vom Hagen1,2, Tobias B Haack3, Christian Wilhelm4, Tobias Lindig5, Stefanie Beck-Wödl6, Sander B Nabuurs7, André BP van Kuilenburg8, Arjan PM de Brouwer9 and Ludger Schöls1,2

Abstract

Background: X-linked Charcot-Marie-Tooth disease type 5 (CMTX5), Arts syndrome, and non-syndromic sensorineural deafness (DFN2) are allelic syndromes, caused by reduced activity of phosphoribosylpyrophosphate synthetase 1 (PRS-I) due to loss-of-function mutations in PRPS1. As only few families have been described, knowledge about the relation between these syndromes, the phenotypic spectrum in patients and female carriers, and the relation to underlying PRS-I activity is limited.

Methods: We investigated a family with a novel PRPS1 mutation (c.830A > C, p.Gln277Pro) by extensive phenotyping, MRI, and genetic and enzymatic tests.

Results: The male index subject presented with an overlap of CMTX5 and Arts syndrome features, whereas his sister presented with prelingual DFN2. Both showed mild parietal and cerebellar atrophy on MRI. Enzymatically, PRS-I activity was undetectable in the index subject, reduced in his less affected sister, and normal in his unaffected mother.

Conclusions: Our findings demonstrate that CMTX5, Arts syndrome and DFN2 are phenotypic clusters on an intrafamilial continuum, including overlapping phenotypes even within individuals. The respective phenotypic presentation seems to be determined by the exact PRPS1 mutation and the residual enzyme activity, the latter being largely influenced by the degree of skewed X-inactivation. Finally, our findings show that brain atrophy might be more common in PRPS1-disorders than previously thought.

Keywords: Ataxia, Early onset ataxia, Genetics, Hearing loss, Optic atrophy, Behr syndrome

Background

Charcot-Marie-Tooth disease-5 (CMTX5, MIM 311070 [1,2]), Arts syndrome (MIM 301835 [3,4]) and X-linked nonsyndromic sensorineural deafness (DFN2; MIM 304500 [5]) present three clinically distinct but genetically allelic disorders, caused by reduced phosphoribosylpyrophosphate synthetase 1 (PRS1) activity due to PRPS1 mutations [6]. Only three families with CMTX5 and two families Arts syndrome, respectively, have been reported worldwide so far [1,3,7]. Thus, evidence is still rare whether these two disorders are separate entities, or rather clusters on a phenotypic continuum of PRPS1-related disease. In addition, knowledge about intrafamilial variability and phenotypic manifestations in female carriers is limited.

Here, we report a family with a novel PRPS1 missense mutation providing several new insights in PRS-I hypoactivity disease. First, features of CMTX5 and Arts syndrome features can overlap within individuals, indicating an intraindividual continuum of these two disorders. Second, CMTX5/Arts and (prelingual, severe) DFN2 can present within one and the same family, revealing an intrafamilial continuum of these disorders. Third, the respective phenotypic...
Methods

The index patient, his sister and his mother were investigated by (i) detailed clinical examination by a specialist in rare neurogenetic disorders, (ii) routine laboratory serum tests including uric acid analysis, (iii) enzymatic analyses of PRS-I activity in erythrocytes (for methodological details, see Additional file 1), and (iv) PRPS1 DNA sequence analysis (for methodological details, see Additional file 2). Additionally, the index patient and his sister were assessed by (v) nerve conduction studies, (vi) ophthalmological funduscopy, and (vii) routine brain magnetic resonance imaging (MRI).

The frequency of the identified PRPS1 variant was determined in more than 4,250 X-chromosomes of European control individuals with unrelated phenotypes analyzed by exome sequencing (for methodological details, see [8]). In addition, the frequency of the change was assessed in the exome variant server (EVS) of the National Heart, Lung, and Blood Institute GO Exome Sequencing Project (Seattle, WA, USA; URL: evs.gs.washington.edu/EVS/) with the corresponding nucleotide positions being analyzed in >8,000 European and >4,000 African American alleles, and in the Database of Single Nucleotide Polymorphisms (dbSNP; Bethesda: National Center for Biotechnology Information, National Library of Medicine [dbSNP Build ID: 138]; available from: http://www.ncbi.nlm.nih.gov/SNP/). In-silico predictions of the pathogenicity of genetic variants were performed using PolyPhen-2 [9], SIFT [10] and MutationTaster [11]. The effect of the amino acid change on the structure of PRPS1 was predicted using the crystal structure of human PRPS1 from [12] (PDB entry 2H06; http://www.pdb.org/) as described before [4]. X-inactivation patterns in female PRPS1 mutation carriers were tested by using the highly polymorphic (CAG)n region of the human androgen receptor gene (HUMARA locus) after methylation-sensitive digestion with HpaII, as described previously [13]. This study was carried out in compliance with the Helsinki Declaration, and approved by the Institutional Review Board of the University of Tübingen, reference number 598/20118O1.

Consent

Written informed consent was obtained from the patients for the publication of this report and any accompanying images.

Results

Clinical assessment

A 36-year-old male patient from non-consanguineous German parents (subject II-2; for pedigree, see Figure 1A; for clinical details see Table 1) presented with prelingual hearing loss since birth, recurrent severe infections from age 6 to 8 years with subsequent partially remitting bulbar paresis and flaccid tetraparesis which never fully resolved, and progressive visual loss due to optic atrophy since age 12 years (current vision at age 36 years: 0.1 right eye, 0.3 left eye). Gait and trunk ataxia started at age 30, leading to a dependency on a walking-frame at age 34 years. Disease severity on the Scale for the Assessment and Rating of Ataxia (SARA) yielded 14 out of 40 points [14]. Behavioural and mental disturbances started at age 16 years, yet the patient was still able to finish secondary school. Already at this time, the patient showed a severely reduced attention span, mental rigidity, low frustration tolerance and aggression to persons including family members. He was unable to perceive and describe his own physical problems during medical visits, rejected social contacts, and neglected the need for medical and rehabilitative treatment. In the following years, he developed attacks of verbal and physical aggression, e.g. repeatedly pulling his mother down to the floor by her hairs at age 35 years. Cycles of aggressive and impulsive behaviour alternated rapidly with cycles of infantile-regressive behaviour, e.g. shouting and crying at age 35 years when confronted with the need for a medical blood sampling. The lack of compliance and cooperative behaviour led to the cessation of examinations required for pre-surgery evaluation for cochlea implants. His cognitive capacities and insight at age 36 years seemed to be below the stage of an adolescent, but no formal neuropsychological testing was possible given his severe hearing and visual impairments and lack of cooperative behaviour.

The combined load of physical, mental and behavioural disturbances required an institutionalization in long-term care since age 35 years. Cerebral MRI demonstrated mild cerebellar and parietal cortical atrophy (Figure 2A,B). Nerve conduction studies showed florid predominant axonal sensorimotor neuropathy (Table 1) with positive sharp waves on EMG of the tibial anterior muscle. Repeated lab testing revealed markedly increased serum creatinkinase (>1000 U/l, ref <190 U/l), probably caused by progressive muscle cell turnover due to florid peripheral neuropathy. In addition, liver transaminases were constantly mildly elevated (AST 60 U/l; ref <50 U/l; ALT 90 U/l; ref <50 U/l), with abdominal sonography showing no structural liver abnormalities.

His sister (subject II-1; Figure 1A) had developed prelingual sensorineural hearing loss in the first years of life, without any further signs of neurological dysfunction at current age of 42 years. This phenotype is fully compatible with the
diagnosis of X-linked non-syndromic sensorineural hearing loss (DFN2) [5]. Her MRI showed discrete parietal and cerebellar atrophy as well (Figure 2C,D). The mother of the two subjects (subject I-1) did not show any hearing deficit or neurological dysfunction at the current age of 66 years. Uric acid in serum was normal in all three subjects (for an overview of all clinical and lab details, see Table 1).

### Serum biomarker and genetic analyses

Based on the initial clinical assumption of an autosomal-recessive ataxia, the index patient was assessed by extensive serum testing for biomarkers indicative of recessive ataxias (alpha-feto protein, lactate, vitamin E, very long chain fatty acids, phytic acid, coeruloplasmin, cholestanol, lysosomal enzymes, carbohydrate-deficient
transferrin, quantitative assessment of amino acids) [15], and genetic testing of FRDA, POLG, PEO1/Twinkle, WFS1, and ABHD12. All results were normal. Sequencing of PRPS1 revealed a novel hemizygous c.830A > C, p. Gln277Pro variant changing a highly conserved amino acid residue (PhyloP score 4.6; Figure 1C), predicted to be damaging by all *in silico* predictions (PolyPhen-2 score: 0.991; SIFT score: 0.01; MutationTaster: disease causing), and not found in 4,200 ethnically-matched control X-chromosomes or in the 6,500 exomes (= 10,562 alleles) of the NHLBI Exome Variant Server (EVS). The same variant was identified in the sister (II-1) and the mother (I-1) of

### Table 1 Clinical findings and further investigations in PRPS1 Gln277Pro mutation carriers

<table>
<thead>
<tr>
<th>Subject</th>
<th>II.2</th>
<th>II.1</th>
<th>I.2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td>m</td>
<td>f</td>
<td>f</td>
</tr>
<tr>
<td>Phenotypic cluster</td>
<td>CMTX5/Arts</td>
<td>DFN2</td>
<td>None</td>
</tr>
<tr>
<td>Current age</td>
<td>36</td>
<td>42</td>
<td>66</td>
</tr>
<tr>
<td>Age of onset first symptom</td>
<td>Congenital, hearing loss</td>
<td>Congenital, hearing loss</td>
<td>None</td>
</tr>
<tr>
<td>Neurological</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mental retardation</td>
<td>(+) progressive aggressive, childish behavior, starting at age 18</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Ataxia (age of onset)</td>
<td>+, 30 years</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Severity of ataxia (SARA score)</td>
<td>14 out of 40</td>
<td>1 out of 40</td>
<td>0 out of 40</td>
</tr>
<tr>
<td>Delayed motor development</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Loss of deep tendon reflexes</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Hearing loss (age of onset)</td>
<td>+, congenital</td>
<td>+, congenital</td>
<td></td>
</tr>
<tr>
<td>Optic atrophy (age of onset)</td>
<td>12</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Uric acid overproduction</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gout</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Kidney stones</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Renal failure</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Serum uric acid (ref 3.4-7.0 mg/dl)</td>
<td>4.3 mg/dl</td>
<td>4.4 mg/dl</td>
<td>4.2 mg/dl</td>
</tr>
<tr>
<td>Hematopoetic</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recurrent infections</td>
<td>(+), only from age 6 to 8 years</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Anemia</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Other</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Short stature</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Self-injury</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Early death</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Lab, electrophysiology and MRI investigations</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nerve conduction studies</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sensory nerve conduction</td>
<td>Sur: no SNAP; Rad: no SNAP</td>
<td>Sur: normal, Rad: normal</td>
<td>n.d.</td>
</tr>
<tr>
<td>Sural or radial nerve</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Motor nerve conduction</td>
<td>Tib: borderline MNCV (40 m/s; ref &gt; 40 m/s); Uln: reduced CMAP (2.1 mV; ref: &gt; 4 mV); reduced MNCV (36 m/s; ref: &gt; 50 m/s)</td>
<td>Tib: normal; Uln: normal</td>
<td></td>
</tr>
<tr>
<td>Tibial or ulnar nerve</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MRI</td>
<td>Mild cerebellar and parietal cortical atrophy</td>
<td>Mild cerebellar and parietal cortical atrophy</td>
<td>n.d.</td>
</tr>
<tr>
<td>Serum creatin kinase (ref &lt;180 U/l)</td>
<td>1168 U/l</td>
<td>141U/l</td>
<td>196 U/l</td>
</tr>
<tr>
<td>PRS-I enzyme activity (ref 0.41-1.46 nmol/(min.mg protein))</td>
<td>&lt;0.005 nmol/(min.mg protein)</td>
<td>0.1 nmol/(min.mg protein)</td>
<td>1.04 nmol/(min.mg protein)</td>
</tr>
</tbody>
</table>

This table was designed to show not only those clinical symptoms that are present, but also those that are absent in this index family, yet common in other PRPS1 patients. The features were selected and extended from de Brouwer et al., 2010 [6]. Legend: m, male; f, female; n.d., not done; ref, reference value; SARA, scale for the Assessment and Rating of Ataxia, reaching from 0 to 40, with higher scores indicating more severe ataxia; scores < 3 points are considered unspecific. Sur = sural; Rad = radial; Tib = tibial; Uln = ulnar; SNAP = sensory nerve action potential; SNCV = sensory nerve conduction velocity; CMAP = compound muscle action potential; MNCV = motor nerve conduction velocity; MRI, magnetic resonance imaging.

This study was supported by the European Community’s Seventh Framework Program (FP7/2007-2013) under grant agreement no. 201072 (EGPAC).
the index patient in a heterozygous state (for electropherograms, see Additional file 3).

Protein structural effects of the PRPS1 mutation
Gln277 is located in the C-terminal domain of PRPS1 and is close to the catalytic active site, which consists of an ATP binding site and a ribose-5-P binding site (Figure 1D). The p.Gln277Pro change results in two sequential prolines, which very likely disrupts the alpha-helical structure of this short helical segment and destabilizes the C-terminal PRPS1 domain. In addition, Gln277 interacts with Gly251, which is close proximity to the R5P binding site (Figure 1E). The p.Gln277Pro change will result in a loss of this hydrogen bonding interaction potentially destabilizing the region surrounding the ribose-5-P binding site, thus affecting the PRPS1 catalytic active site. When comparing the protein structural effects of all known PRPS1 mutations and their relations to PRPS1-phenotypic clusters, the p.Gln277Pro (Q277P) mutation falls in between CMTX5 and Arts syndrome PRPS1 mutations. Like other Arts syndrome mutations (and in contrast to CMTX5 PRPS1 mutations), it is predicted to disrupt the local PRS-I structure. However, unlike the other Arts syndrome mutations and in line with the CMTX PRPS1 mutations, it is not predicted to disturb the allosteric site II or to affect the dimer interface (Table 2).

Enzyme activity
PRS-I activity was not detectable in erythrocytes the index patient II-2 (<0.005 nmol/[min.mg protein]; reference value: 0.41-1.46 nmol/[min.mg protein]), reduced to 0.10 nmol/[min.mg protein] in his sister (II-1), and normal in their mother (I-1; 1.04 nmol/[min.mg protein]) (Figure 1B).

X- chromosome inactivation (XCI)
XCI was extremely skewed (defined as ratio >90%;10% [16]) in II-1 (94%;6%), but only moderately skewed in I-1 (80%;20%).
Here we report a family with a novel PRPS1 mutation which provides new insights in PRPS1-related disease. The index patient (subject II-2) showed an overlapping phenotype combining features of both CMTX5 and (mild, relatively late-onset) Arts syndrome. Prelingual hearing loss, optic atrophy with onset in the teens and severe sensorimotor neuropathy are part of the classical CMTX5 triad [2]. However, recurrent infections in childhood leading to acute deteriorations of slowly progressive muscle weakness, severe ataxia leading to walker-dependency, mild to moderate mental and behavioural deficits, and institutionalization in homes for physically and mentally handicapped are all features not reported in previous CMTX5 subjects, but known from subjects with Arts syndrome (though usually in a more severe early-onset form) [3,17]. This shows that CMTX5 and Arts syndrome can overlap within one and the same individual, thus indicating a continuous spectrum of PRS1-hypoactivity disease. This finding corroborates and extends the recent observation from one individual with PRS-I superactivity who showed not only signs of PRS-I superactivity syndrome, but also of Arts syndrome [18]. Taken together, these findings indicate that both PRS1 superactivity and PRS-I hypoactivity disorders form a continuous gradual spectrum of disease.

The notion of a continuous disease spectrum of PRS1-hypoactivity disorders is further supported by our observation that a CMTX5/Arts overlapping phenotype can co-occur within the same family as a DFN2 phenotype (subject II-1), demonstrating an intrafamilial continuum of these three clusters of PRS1-hypoactivity diseases. So far, CMTX5, Arts syndrome and DFN2 were only reported in different families, not within the same family [6]. An earlier report already indicated that some subjects can present with an only incomplete presentation of a PRPS1 disease cluster (e.g. absence of optic atrophy in CMTX5 subjects [7]). Taken together, these findings suggest a continuous spectrum of PRPS1 disease features, where hearing loss, peripheral neuropathy, optic atrophy, ataxia, cognitive deficits and recurrent infections are central, yet variable phenotypic features. Along this spectrum, the established PRPS1 disease clusters are

**Table 2 Predicted structural effects of known PRPS1 mutations**

<table>
<thead>
<tr>
<th>Mutation</th>
<th>Disturbance of local structure</th>
<th>Affecting dimer interface</th>
<th>Affecting trimer interface</th>
<th>Disturbance of ATP binding site</th>
<th>Disturbance of allosteric site I</th>
<th>Disturbance of allosteric site II</th>
<th>Neuropathy</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PRS-I superactivity</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>p.D52H</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td></td>
<td>+</td>
<td></td>
<td>-</td>
</tr>
<tr>
<td>p.N144S</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td></td>
<td>+/-</td>
<td>+/-</td>
<td>+</td>
</tr>
<tr>
<td>p.L129I</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td></td>
<td>+</td>
<td></td>
<td>-</td>
</tr>
<tr>
<td>p.D183H</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td></td>
<td>+/-</td>
<td>+/-</td>
<td>+</td>
</tr>
<tr>
<td>p.A190V</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td></td>
<td>+/-</td>
<td>+/-</td>
<td>+</td>
</tr>
<tr>
<td>p.H193L**</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td></td>
<td>+/-</td>
<td>+/-</td>
<td>-</td>
</tr>
<tr>
<td>p.H193Q</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td></td>
<td>+/-</td>
<td>+/-</td>
<td>+</td>
</tr>
<tr>
<td>p.V142L</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td>+</td>
</tr>
<tr>
<td><strong>Arts syndrome</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>p.Q133P</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td>+</td>
</tr>
<tr>
<td>p.L152P</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td>+</td>
</tr>
<tr>
<td>p.Q277P</td>
<td>+</td>
<td>-</td>
<td>+/-</td>
<td></td>
<td></td>
<td></td>
<td>+</td>
</tr>
<tr>
<td><strong>CMTX5</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>p.E43D</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td></td>
<td>+</td>
<td></td>
<td>-</td>
</tr>
<tr>
<td>p.M115T</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td></td>
<td>+</td>
<td></td>
<td>-</td>
</tr>
<tr>
<td>p.A121G</td>
<td>+</td>
<td>-</td>
<td>+/-</td>
<td></td>
<td>+/-</td>
<td>+/-</td>
<td>-</td>
</tr>
<tr>
<td><strong>DFN2</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>p.D65N</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td></td>
<td></td>
<td></td>
<td>-</td>
</tr>
<tr>
<td>p.A87T</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td>?</td>
</tr>
<tr>
<td>p.I290T</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td>?</td>
</tr>
<tr>
<td>p.G306R</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td></td>
<td></td>
<td></td>
<td>?</td>
</tr>
</tbody>
</table>

When comparing the protein structural effects of all known PRPS1 mutations and their relations to PRPS1-phenotypic clusters, the p.Gln277Pro mutation falls in between CMTX5 and Arts syndrome PRPS1 mutations. Like other Arts syndrome mutations (and in contrast to CMTX5 PRPS1 mutations), it is predicted to disrupt the local PRS1 structure. However, unlike the other Arts syndrome mutations (and in line with other CMTX PRPS1 mutations), it is not predicted to disturb the allosteric site II or to affect the dimer interface. This table was selected, updated and extended from de Brouwer et al., 2010 [6]. Please see here also for further references [6]. **This mutation was found in a female patient.**

**Discussion**

Here we report a family with a novel PRPS1 mutation which provides new insights in PRPS1-related disease. The index patient (subject II-2) showed an overlapping phenotype combining features of both CMTX5 and (mild, relatively late-onset) Arts syndrome. Prelingual hearing loss, optic atrophy with onset in the teens and severe sensorimotor neuropathy are part of the classical CMTX5 trias [2]. However, recurrent infections in childhood leading to acute deteriorations of slowly progressive muscle weakness, severe ataxia leading to walker-dependency, mild to moderate mental and behavioural deficits, and institutionalization in homes for physically and mentally handicapped are all features not reported in previous CMTX5 subjects, but known from subjects with Arts syndrome (though usually in a more severe early-onset form) [3,17]. This shows that CMTX5 and Arts syndrome can overlap within one and the same individual, thus indicating a continuous spectrum of PRS1-hypoactivity disease. This finding corroborates and extends the recent observation from one individual with PRS-I superactivity who showed not only signs of PRS-I superactivity syndrome, but also of Arts syndrome [18]. Taken together, these findings indicate that both PRS1 superactivity and PRS-I hypoactivity disorders form a continuous gradual spectrum of disease.

The notion of a continuous disease spectrum of PRS1-hypoactivity disorders is further supported by our observation that a CMTX5/Arts overlapping phenotype can co-occur within the same family as a DFN2 phenotype (subject II-1), demonstrating an intrafamilial continuum of these three clusters of PRS-I hypoactivity diseases. So far, CMTX5, Arts syndrome and DFN2 were only reported in different families, not within the same family [6]. An earlier report already indicated that some subjects can present with an only incomplete presentation of a PRPS1 disease cluster (e.g. absence of optic atrophy in CMTX5 subjects [7]). Taken together, these findings suggest a continuous spectrum of PRPS1 disease features, where hearing loss, peripheral neuropathy, optic atrophy, ataxia, cognitive deficits and recurrent infections are central, yet variable phenotypic features. Along this spectrum, the established PRPS1 disease clusters are
not separate entities, but endophenotypes on a pheno-
typic continuum.

Female carriers in families with Arts syndrome were
known to sometimes exhibit some hearing impairment
later in life (age >20 years) combined with ataxia and
neuropathy [3,19]; yet prelingual hearing loss starting at
birth - as observed in subject II-1 - has not yet been de-
scribed in these families. Female carriers in families with
CMTX5 are noted to be asymptomatic [1]. Our findings
indicate that these current notions and corresponding
counselling recommendations of female carriers in fam-
ilies with CMTX5 [1] or Arts syndrome [3] should be re-
vised: female carriers in families with these phenotypic
clusters can show symptoms already very early in life,
leading to substantial impairment in everyday social life.

How might this intrafamilial continuum of PRPS1 dis-
edase clusters be explained? Our results indicate that the
respective phenotypic presentation seems to be deter-
mined by (1.) the exact PRPS1 mutation (in males) and
(2.) the residual enzyme activity, which in turn is largely
influenced by the degree of skewed X-inactivation (in fe-
males). The predicted structural effects of the p.Gln277Pro
mutation fall in between those of the CMTX5 and Arts
syndrome PRPS1 mutations (Table 2), thus explaining the
CMTX/Arts syndrome overlapping phenotype in the male
index patient II-2. PRS-I enzyme activity was not detect-
able in this male subject with the most complex and se-
vere phenotype, while it was moderately reduced in his
sister II-1 with a nonsyndromic hearing loss phenotype
(DFN2), and normal in his unaffected mother I-1.

(Figure 1B). The lack of detectable PRS-I activity in sub-
ject II-2 might explain why his phenotypic presentation
included components of the Arts cluster, as absence of
PRS-I activity has already been reported for patients with
a pure Arts phenotype [4]. The residual PRS-I activity in
the female carriers (I-1; II-1) might be explained by com-
ensation through the second (intact) X chromosome.
PRS-I activity was lower in subject II-1 than in subject I-1,
most likely due to severely skewed X-chromosome inacti-
vation which was observed in this subject. Alternatively,
tissue-specific control of other genetic and epigenetic
mechanisms might explain the differences in PRS1 activity
between I-1 and II-1, e.g. the regulation of PRPS1 by
microRNA-376 [17] and difference in expression levels
and function of the other three PRS isoforms [6]. Our
finding of a clinico-enzymatic correlation between enzym-
atic activity and disease severity indicates that PRS-I activ-
ity may serve as a blood biomarker for PRPS1 disease
and may help to corroborate pathogenicity of novel PRPS1
variants of unknown significance. It also suggests that it
might serve as an interesting readout and surrogate par-
ameter for treatment efficacy.

So far, cerebral MRI abnormalities have been ob-
served neither in CMTX5 nor in Arts syndrome [3],
yet such abnormalities are likely given the wide range of
clinical central nervous abnormalities in PRPS1-dis-
orders, in particular in Arts syndrome. Here we show
that mild signs of cerebellar and parietal atrophy can be
seen in both subject II-2 and subject II-1, thus pro-
viding first evidence for structural central nervous
system damage in PRPS1- disease. As atrophy is very
mild, it might have been present also in previous
PRPS1 subjects, yet not been recognized. Our finding
of a subject with adolescent-onset ataxia with neur-
opathy, optic atrophy, hearing loss, and mild atrophy
of the cerebellum without evidence of neurological
disease in the parental generation places PRPS1-dis-
ease in the differential diagnosis of many adult-onset
autosomal-recessive and mitochondrial ataxias where
such findings are common and which might be mimicked
by PRPS1-disease. This differential diagnosis includes
e.g. OPA3/Type III methylglutaconic aciduria (MIM
606580), OPA1 (MIM 605290) or Wolfram Syndrome
(MIM 606201).

Conclusions
Our findings indicate that CMTX5, Arts syndrome and
DFN2 are phenotypic clusters on a continuous intraindi-
vidual and intrafamilial spectrum of PRPS1-disease. The
respective phenotypic presentation seems to depend on the
exact PRPS1 mutation and the residual enzyme activity
and skewed X-inactivation, respectively.

Additional files

Additional file 1: PRS-I Activity Analysis.
Additional file 2: PRPS1 sequencing by PCR (Sanger sequencing).
Additional file 3: Electropherograms of PRPS1 sequencing.

Abbreviations
CMTX5: Charcot-Marie-Tooth disease 5; DFN2: X-linked non-syndromic
sensorineural deafness; EMG: Electromyography; MRI: Magnetic resonance
imaging; PRS1: Phosphoribosylpyrophosphate synthetase 1.

Competing interests
Dr. Synofzik received honoraria from Actelion Pharmaceuticals Ltd.
Dr. J. Müller vom Hagen received honoraria from Actelion Pharmaceuticals Ltd.
Dr. Haack reports no disclosures.
Dr. Wilhelm reports no disclosures.
Dr. Lindig received a travel grant by Bayer HealthCare.
Dr. Beck-Wödl received a travel grant by Actelion Pharmaceuticals Ltd.
Dr. van Kuijlenburg reports no disclosures.
Dr. de Brouwer reports no disclosures.
Dr. Schöls reports no disclosures.

Authors’ contributions
MS: conceptualization of the study, acquisition of data, analysis of the data,
drafting the manuscript. JMvH: acquisition of data, revising the manuscript.
TBH: acquisition of data, revising the manuscript. CW: acquisition of data,
revising the manuscript. ABPvK: acquisition of data, revising the manuscript.
APMdB: acquisition of data, revising the manuscript. LS: supervision of the

study, acquisition of data, revising the manuscript. All authors read and approved the final manuscript.

Acknowledgements
We thank the patients and their family for their invaluable support and cooperation, and Jeroen Roelofsen for assistance with investigating PRS-I enzyme activity. This work was supported by the European Community's Seventh Framework Programme to Neuromics (F5-2012-305121 to LS), and the EU FP7 Large-Scale Integrating Project Genetic and Epigenetic Networks in Cognitive Dysfunction (GENCODYS; grant no. 241995).

We acknowledge support by Deutsche Forschungsgemeinschaft and Open Access Publishing Fund of Tuebingen University.

Author details
1Department of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research, University of Tuebingen, Tuebingen, Germany. 2German Research Center for Neurodegenerative Diseases (DZNE), Tuebingen, Germany. 3Institute of Human Genetics, Technische Universität München, Munich, Germany. 4CeGaT GmbH, Center for Genomics and Transcriptomics, Tuebingen, Germany. 5Diagnostic and Interventional Neuroradiology, University Hospital Tuebingen, Tuebingen, Germany. 6Institute of Medical Genetics and Applied Genomics, University of Tuebingen, Tuebingen, Germany. 7Institute of Human Genetics, Technische Universität München, Munich, Germany. 8Institute of Medical Genetics and Applied Genomics, University of Tuebingen, Tuebingen, Germany. 9Department of Radiology, University Hospital Tübingen, Tübingen, Germany. 5Diagnostic and Interventional Neuroradiology, University Hospital Tübingen, Tübingen, Germany. 4CeGaT GmbH, Center for Genomics and Transcriptomics, Tuebingen, Germany. 6Institute of Medical Genetics and Applied Genomics, University of Tuebingen, Tuebingen, Germany. 7Institute of Human Genetics, Technische Universität München, Munich, Germany. 8Institute of Medical Genetics and Applied Genomics, University of Tuebingen, Tuebingen, Germany. 9Department of Radiology, University Hospital Tübingen, Tübingen, Germany.

Received: 17 December 2013 Accepted: 10 February 2014

Published: 14 February 2014

References


